Clinical Trial Update: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating different doses of Brigimadlin in combination with Ezabenlimab, with an arm including BI-754111, in patients with advanced solid tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BI-754111
• brigimadlin (brigimadlin)
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED